StockTipsArenaBeta

BUY Emcure Pharmaceuticals Limited — Anshul Jain, Lakshmishree Investment and Securities

BUYEmcure Pharmaceuticals Limited
Emcure Pharmaceuticals share price target & all analyst calls

byAnshul Jain, Lakshmishree Investment and SecuritiesHorizon: NA (inferred 1–3 months)15 Apr 2026via Business Today

Entry₹1,568Inferred
Target₹2,000
Total upside +27.55% (call closed)
Stop lossNot given
At expiry₹1,790.315 Jul 2026, 3:30 pm
Expired+14.18%
Follow Anshul Jain for new calls(18% target hit, 11 closed calls)Get alertsWatch EMCURE for new buy/sell callsGet alertsSee 45 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 23 Oct, 1:26 am IST
7 supporting1 neutral0 opposing
Supports the BUY call (7)

Emcure Pharmaceuticals Ltd's press release indicates consolidation of Gennova ownership and a sharpened focus on biologics, with Samit Mehta leading growth.

BSE · Company Update·13 Jul · yesterday

(opens in new tab)

Emcure Pharmaceuticals Limited is acquiring an additional 12.05% stake in its subsidiary, Gennova Biopharmaceuticals Limited, for Rs. 2,318.7 Million. This acquisition will make Gennova a wholly-owned

NSE · Acquisition·13 Jul · yesterday

(opens in new tab)

Emcure Pharmaceuticals Ltd has executed Share Transfer Agreements to acquire an additional 12.05% stake in Gennova Biopharmaceuticals Ltd, making Gennova a wholly-owned subsidiary upon completion. The

BSE · Company Update·13 Jul · yesterday

(opens in new tab)

2 other SEBI-registered advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · same horizon·8 Jul · 1w ago

Emcure Pharmaceuticals Limited's subsidiary, Marcan Pharmaceuticals Inc., has acquired all Class E Special Shares in its step-down subsidiary, Mantra Pharma Inc., for CAD $50 million. This acquisition

NSE · Acquisition·3 Jul · 2w ago

(opens in new tab)
Neutral / worth noting (1)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Emcure Pharmaceuticals

All analyst calls on Emcure Pharmaceuticals

More from Anshul Jain, Lakshmishree Investment and Securities

Every call and its outcome